Vasopeptidase inhibitors: an emerging class of cardiovascular drugs

This publication has 21 references indexed in Scilit:

• Fasidotril: The First Dual Inhibitor of Neprilysin and ACE
  Cardiovascular Drug Reviews, 2006
• In Vitro and In Vivo Inhibition of the 2 Active Sites of ACE by Omapatrilat, a Vasopeptidase Inhibitor
  Hypertension, 2000
• Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans.
  Hypertension, 2000
• Vasopeptidase Inhibition with Omapatrilat Improves Cardiac Geometry and Survival in Cardiomyopathic Hamsters More Than Does ACE Inhibition with Captopril
  Journal of Cardiovascular Pharmacology, 1999
• Emerging treatments for hypertension: potential role for vasopeptidase inhibition.
  American Journal of Hypertension, 1999
• Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects
  American Journal of Hypertension, 1999
• Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension*
  Clinical Pharmacology & Therapeutics, 1998
• Section Review: Cardiovascular & Renal: Recent advances in the development of dual angiotensin-converting enzyme and neutral endopeptidase inhibitors
  Expert Opinion on Therapeutic Patents, 1996
• Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril.
  Proceedings of the National Academy of Sciences, 1991
• Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan.
  Proceedings of the National Academy of Sciences, 1989